Leyden Labs raised $20M in funding, led by the European Investment Bank, to expand operations and enhance R&D efforts.
Leyden Labs raised $20M in funding, led by the European Investment Bank, to expand operations and enhance R&D efforts.
06/04/25, 8:35 AM
Location
leidenMoney raised
$20 million
Industry
biotechnology
Investors
European Investment Bank
Leyden Labs, a Leiden, the Netherlands-based clinical-stage biotechnology company, raised $20M in funding. The round was led by the European Investment Bank. The company intends to use the funds to expand operations and its R&D efforts. Led by CEO Koenraad Wiedhaup, Leyden Labs is developing therapies to treat respiratory viruses.
Company Info
Location
leiden, south holland, netherlands
Additional Info
Leyden Labs aims to help people live their lives to the fullest. Our platform targets commonalities of viral families to protect humanity from known and future viruses. Our portfolio of accessible intranasal product candidates may provide people with the freedom to immediately protect themselves from and prevent the spread of many variants of respiratory viruses, including ones in the influenza and coronavirus families.
The Leyden Labs’ energetic team of world-renowned biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses.